Grifols (NASDAQ:GRFS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Grifols (NASDAQ:GRFS) from a buy rating to a strong-buy rating in a research report released on Saturday morning.

Separately, JPMorgan Chase & Co. boosted their price objective on Grifols from $7.60 to $10.30 and gave the stock a “neutral” rating in a report on Tuesday, June 17th.

Grifols Trading Down 4.6%

Shares of NASDAQ:GRFS opened at $8.37 on Friday. Grifols has a 12-month low of $5.79 and a 12-month high of $9.96. The stock has a market cap of $5.75 billion, a PE ratio of 7.15, a P/E/G ratio of 0.32 and a beta of 0.53. The business has a 50 day moving average of $7.92 and a 200-day moving average of $7.62. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13.

Institutional Investors Weigh In On Grifols

Institutional investors have recently made changes to their positions in the stock. Norges Bank bought a new stake in shares of Grifols in the fourth quarter valued at approximately $14,434,000. LPL Financial LLC boosted its stake in shares of Grifols by 25.0% in the fourth quarter. LPL Financial LLC now owns 75,398 shares of the biotechnology company’s stock valued at $561,000 after buying an additional 15,067 shares during the period. First Trust Advisors LP bought a new stake in shares of Grifols in the fourth quarter valued at approximately $75,000. GAMMA Investing LLC boosted its stake in shares of Grifols by 426.1% in the first quarter. GAMMA Investing LLC now owns 26,087 shares of the biotechnology company’s stock valued at $1,850,000 after buying an additional 21,128 shares during the period. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in shares of Grifols in the fourth quarter valued at approximately $77,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.